PD58-12 CROSS-REACTIVITY BETWEEN THE FIRST-LINE CHEMOTHERAPY AND SUBSEQUENT IMMUNOTHERAPY IN PATIENTS WITH UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA. (May 2022)